Editas Medicine (EDIT) Receivables - Net (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Receivables - Net of $15.2 million for Q4 2025, down 6.7% year-over-year from $16.3 million in Q4 2024, and up 86.67% quarter-over-quarter from $8.1 million in Q3 2025.
Editas Medicine (EDIT) Receivables - Net (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Receivables - Net for 11 consecutive years, with $15.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Net fell 6.7% year-over-year to $15.2 million; the TTM figure through Dec 2025 stood at $15.2 million (down 6.7% YoY), while the FY2025 annual figure was $15.2 million, down 6.7% from the prior year.
- Receivables - Net improved to $15.2 million in Q4 2025 per EDIT's latest filing, from $8.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $16.3 million in Q4 2024 and bottomed at $120000.0 in Q3 2022.
- Historically, Receivables - Net has averaged $3.3 million across 5 years, with a median of $630000.0 in 2021.
- Annual changes were most pronounced in 2021 — Receivables - Net sank 95.59% — and 2025, when it surged 6352.38%.
- Editas Medicine's Receivables - Net stood at $267000.0 in 2021, then jumped by 1826.97% to $5.1 million in 2022, then surged by 98.0% to $10.2 million in 2023, then soared by 59.67% to $16.3 million in 2024, then fell by 6.7% to $15.2 million in 2025.
- Business Quant data shows EDIT's Receivables - Net at $15.2 million in Q4 2025, $8.1 million in Q3 2025, and $588000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.18 Mn |
| Dec 31, 2025 | 15.18 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 588,000.00 |
| Jun 30, 2025 | 588,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 16.27 Mn |
| Dec 31, 2024 | 16.27 Mn |
| Sep 30, 2024 | 126,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 10.19 Mn |
| Dec 31, 2023 | 10.19 Mn |
| Sep 30, 2023 | 2.42 Mn |
| Sep 30, 2023 | 2.42 Mn |